2Q EARNINGS: Valeant dives on lower guidance; Allergan deal value takes a hit
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticals closed down 6.7% at $117.39 per share on 31 July after the Canadian specialty pharma company lowered its full-year 2014 revenue and earnings guidance despite an 86% year-over-year increase in second quarter sales to $2bn and a 43% jump in adjusted income to $651m or $1.91 per share.